Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June
June 04 2024 - 11:35AM
Valneva to Present and Hold Investor Meetings at Upcoming
Conferences in June
Saint-Herblain (France), June 4,
2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a
specialty vaccine company, today announced that management will
participate at several upcoming investor conferences in the United
States and Europe during June 2024.
Valneva will present and meet with global
institutional investors to discuss VLA15, the world’s leading Lyme
Disease vaccine candidate, in Phase 3 development and partnered
with Pfizer; the Company’s growing commercial business, including
ongoing launch plans for IXCHIQ®, the world’s first and only
approved chikungunya vaccine; and VLA1601, its second-generation
Zika virus vaccine candidate, currently in Phase 1 clinical
development.
Institutional investors who would like to meet
1on1 with management at any of the below conferences are asked to
submit a request to their representative at the respective
bank.
Jefferies Global Healthcare Conference
Date/time:
June
6, 2:00pmFormat:
Fireside
chat and investor
meetingsWebcast: https://wsw.com/webcast/jeff302/valn/1846928.
A replay of the webcast will be available following the live events
in the “Investor” section of the Valneva
website.Location: New
York, NY
13th ODDO BHF Nextcap Forum
Date:
June
6Format: Investor
meetings
onlyLocation: Virtual
Goldman Sachs 45th Annual Global Healthcare
Conference:
Date June
10 –
13Format: Fireside
chat and investor meetingsLocation
Miami,
FL
Stifel 2nd European Healthcare Summit
Date: June
25 –
27Format: Investor
meetings
onlyLocation: Lyon,
France
About Valneva SEWe are a
specialty vaccine company that develops, manufactures, and
commercializes prophylactic vaccines for infectious diseases
addressing unmet medical needs. We take a highly specialized and
targeted approach, applying our deep expertise across multiple
vaccine modalities, focused on providing first-, best- or
only-in-class vaccine solutions.
We have a strong track record, having advanced
multiple vaccines from early R&D to approvals, and currently
market three proprietary travel vaccines as well as certain
third-party vaccines leveraging our established commercial
infrastructure.
Revenues from our growing commercial business
help fuel the continued advancement of our vaccine pipeline. This
includes the only Lyme disease vaccine candidate in advanced
clinical development, which is partnered with Pfizer, as well as
vaccine candidates against the Zika virus and other global public
health threats.
Valneva Investor and Media ContactsLaetitia
Bachelot-FontaineVP, Global Communications and European Investor
RelationsM +33 (0)6 4516
7099laetitia.bachelotfontaine@valneva.com |
Joshua Drumm, Ph.D.VP, Global Investor Relations M +001
917 815 4520joshua.drumm@valneva.com |
|
|
Forward-Looking Statements
This press release contains certain
forward-looking statements relating to the business of Valneva,
including with respect to the progress, timing, results and
completion of research, development and clinical trials for product
candidates, to regulatory approval of product candidates and review
of existing products. In addition, even if the actual results or
development of Valneva are consistent with the forward-looking
statements contained in this press release, those results or
developments of Valneva may not be sustained in the future. In some
cases, you can identify forward-looking statements by words such as
“could,” “should,” “may,” “expects,” “anticipates,” “believes,”
“intends,” “estimates,” “aims,” “targets,” or similar words. These
forward-looking statements are based largely on the current
expectations of Valneva as of the date of this press release and
are subject to a number of known and unknown risks and
uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from any
future results, performance or achievement expressed or implied by
these forward-looking statements. In particular, the expectations
of Valneva could be affected by, among other things, uncertainties
and delays involved in the development and manufacture of vaccines,
unexpected clinical trial results, unexpected regulatory actions or
delays, competition in general, currency fluctuations, the impact
of the global and European credit crisis, and the ability to obtain
or maintain patent or other proprietary intellectual property
protection. Success in preclinical studies or earlier clinical
trials may not be indicative of results in future clinical trials.
In light of these risks and uncertainties, there can be no
assurance that the forward-looking statements made during this
presentation will in fact be realized. Valneva is providing the
information in these materials as of this press release and
disclaim any intention or obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events, or otherwise.
Valneva (EU:VLA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Valneva (EU:VLA)
Historical Stock Chart
From Sep 2023 to Sep 2024